JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 43(2009) N 6 p. 917-929;
M.Yu. Skoblov

Prospects of antisense therapy technologies

Medical Genetic Research Center, Russian Academy of Medical Sciences, Moscow, 115478, Russia
Received - 2009-01-22; Accepted - 2009-01-11

Three variants of antisense technologies are presently known: antisense oligonucleotides, RNA interference, and ribozymes. In spite of the difference in the mechanisms of action, all of them are based on a common principle: an antisense preparation works after binding with an RNA target to form a duplex. All of the three variants are intensely used in experiments in vivo. The review considers the current situation in the field of using antisense technologies to treat various diseases.

antisense therapy, antisense oligonucleotides, RNA interference, ribozymes



JMB-FOOTER RAS-JOURNALS